Vulvar (vulval) cancer affects external genital tissue. This guide focuses on adult invasive squamous disease. NHS definition; NCI scope.
- Persistent itching, a lump, ulcer or unusual bleeding needs examination. NHS symptoms.
- Biopsy assesses suspicious tissue; imaging helps establish extent. NCI diagnosis.
- Surface VIN and invasive cancer require distinct decisions. NCI definition.
- Treatment and groin-node assessment depend on the actual diagnosis. NCI options.
Table of contents
- Evidence summary
- Histology
- Diagnosis
- Local treatment
- Support and supplements
- Extent and goals
- Urgent help
- Coordination
- Individual care
- Follow-up
- Laboratory evidence
- Funding and source roles
- Frequently asked questions
- Sources and funding notes
Evidence summary
Clinical descriptions, care guidance and independently established treatment outcomes have different evidentiary roles. The table identifies what the reviewed sources can support and which financial or clinical questions remain unresolved.
| Question / approach | Evidence reviewed | Funding / conflicts | Interpretation / limits |
|---|---|---|---|
| Diagnosis | NCI; NHS | Page/contributor payments unclosed | Tissue and extent assessment, not self-diagnosis. |
| Care framework | NCI; ESGO | Author ties; trial money unclosed | Attributed guidance; no independent benefit estimate. |
| Complementary products | NCCIH | Federal/gift routes; contributor/study gaps | Safety context; no supplement efficacy verdict. |
Histology
The vulva includes the labia and clitoris; it is outside the vagina. Vulvar, vaginal and cervical cancers arise at different sites. The diagnosis therefore needs its exact site recorded, rather than the broad label “gynecological cancer.” Vulval and vulvar are spelling variants, not two diseases. NHS anatomy.
Vulvar intraepithelial neoplasia (VIN) means abnormal cells confined to surface tissue. It can precede invasive disease, but it is not automatically an invasive cancer. The clinical question is whether cancer cells have invaded deeper tissue, not whether a visible patch looks large or has caused itching. A precursor diagnosis needs its own specialist management. NCI distinction.
Squamous disease predominates; other histologies need separate pathways. NCI scope.
Diagnosis
Seek a GP or appropriate clinician for persistent itching, a lump, sore or ulcer, non-period bleeding, changing skin colour or thickness, a changing mole, or burning with urination. These symptoms have other common causes. Neither having them nor receiving an urgent referral establishes cancer. During examination you can request a chaperone or support person, explain discomfort and ask to stop. NHS assessment.
Pathology distinguishes HPV-associated and HPV-independent cancers; photographs cannot establish that distinction. ESGO pathology.
Risk is higher with age, smoking, weakened immunity and certain vulvar conditions, including VIN, lichen sclerosus or lichen planus. Risk is not destiny, and the cause is not always known. Ask about appropriate treatment of skin disease, smoking support and locally applicable HPV vaccination. Condoms reduce HPV exposure but do not cover all genital skin. NHS risks.
A vulvoscopy uses magnification to inspect the area. A biopsy removes a small tissue sample, often with local anaesthetic, for a pathologist. This is not the same as a cervical smear. Mild soreness or bleeding can follow sampling; obtain your clinic’s aftercare and contact instructions. NHS biopsy.
The pathologist examines tissue for cancer. Selected imaging such as MRI, CT or PET can assess the extent of disease; it does not replace identifying the sampled lesion. Ask what each proposed test answers and how the team will combine the findings. A cervical test examines another site and cannot by itself settle the identity of a vulvar lesion. NCI assessment.
Local treatment
Surgery may remove a local tumour or part or all of the vulva; groin nodes may also need assessment or removal. Reconstruction can sometimes restore tissue after a larger operation. The plan depends on site, type, size, spread and general health. Ask what structures and nodes are involved, why that extent is proposed and what recovery may entail. These are clinician-led choices, not home eligibility rules. NHS surgery.
NCI’s stage-based options include selected sentinel-node assessment, more extensive groin surgery and radiation in different circumstances. “Sentinel” describes an assessment pathway, not a guarantee that other nodes are clear. Discuss the actual pathology and planned nodal approach rather than choosing by stage name alone. NCI stage-based options.
Radiotherapy directs high-energy radiation at a treatment area, sometimes with surgery, and can relieve symptoms. Adjuvant treatment follows surgery to address remaining risk. Ask about its purpose, field and anticipated effects. This guide provides no radiation dose or comparative benefit estimate. NCI treatment classes.
Support and supplements
Vulvar cancer is more common in older adults, especially after 65, but anyone with a vulva can be affected. Age alone does not exclude the diagnosis; vaccination eligibility and skin-disease care still need an individual discussion. NHS age and risk.
A clinical nurse specialist and cancer team can help with questions and finding suitable local support. Emotional, practical and social support matters throughout assessment and treatment. Ask about services for you and people supporting you, especially if uncertainty or the diagnosis is difficult to discuss. Available organizations and contact routes vary by country; verify local arrangements with your team. NHS support.
Do not replace or delay cancer assessment or treatment with supplements, diets or herbal products. Some products interfere with treatment. NCCIH’s dated safety account describes uncertainty around antioxidant supplements during cancer therapy and tissue damage from black salves. Discuss the exact product and ingredients before use. This review establishes no supplement cure, recurrence prevention or independently cleared symptom-benefit estimate. NCCIH safety.
Extent and goals
Stage describes how far cancer extends, including involvement of nearby structures, regional nodes or distant sites. Regional groin-node involvement and distant metastasis are different findings. Recurrence means cancer has returned after treatment, locally or elsewhere. Ask the team to explain the staging system and your findings together; do not infer prognosis from a single number or confuse all stage IV disease with distant spread. NCI staging.
Locally advanced and recurrent disease can require combinations of surgery, radiation and systemic treatment. Decisions depend on earlier treatment, current extent, health and preferences. Clinical trials may be an option. The older educational menu is not a complete current approval list: specialist review must consider the actual histology, biomarkers, local licence and available studies. NCI selected options.
The NHS describes palliative support when cancer cannot be cured. Ask whether treatment aims at cure, control or relief and what support is available. Distressing symptoms still need care. NHS treatment goals.
Urgent help
Cancer drugs can cause fatigue, nausea, mouth or bowel problems, bleeding or bruising, nerve symptoms and increased infection risk. Effects vary; obtain a written contact plan. Symptoms may have other causes but still need assessment. NHS effects.
Call the cancer team now for possible infection during chemotherapy, including feeling hot, cold or shivery, or for signs of a blood clot such as a painful swollen limb, sudden breathlessness, chest pain or coughing blood. If you cannot reach the team, NHS advice is UK 111; elsewhere use your urgent care service. Emergency signs override that route. NHS urgent advice.
Call 999 or local emergency services for suspected sepsis with confusion, slurred speech, rapid or difficult breathing, or blue, pale, grey or blotchy skin. Not every sign must be present. Do not drive yourself or wait for a routine appointment. Bring medicines if possible without delaying emergency care. These warning signs require assessment whatever their cause. NHS emergency signs.
Coordination
Ask the oncology pharmacist to reconcile medicines and complementary products. This article cannot clear unlisted combinations or decide when to pause essential treatment. Follow your care team’s instructions. NCCIH safety.
Discuss lasting physical or psychological effects, swelling and sexual concerns. ESGO describes lymphoedema and psychosexual support in follow-up. ESGO support framework.
Individual care
Cancer therapy needs a prescribed schedule and assessment plan. Chemotherapy timing varies with the medicine, cancer and response; treatment may alternate with rest periods. The team may use examinations, blood tests or scans to monitor progress. If side effects require a schedule change, the clinician should explain what to do and when to restart. A treatment break is not an instruction to improvise a longer pause or resume medicines independently. NCI supervised care.
The treatment menu for VIN includes surface-directed procedures and, in selected circumstances, topical medicines. That does not establish a home cream treatment for invasive squamous cancer. Do not apply a precursor option to a biopsy showing invasion, or assume a visible lesion has disappeared completely because symptoms improve. The diagnosis and treatment goal must remain explicit. NCI separate VIN menu.
Tell the team promptly about possible pregnancy; discuss fertility goals before chemotherapy. Some treatments affect fertility. Pregnancy and contraception decisions require the actual medicine and situation; no universal reassurance, timetable or interruption rule is given here. NHS pregnancy planning.
Follow-up
Treatment response is assessed using clinical review and selected tests or scans. Strong side effects do not prove that chemotherapy is working, and few side effects do not prove failure. If mouth or bowel problems interfere with eating, tell the team; a dietitian may help assess suitable support. Do not skip or reschedule therapy using symptoms as a response test: the clinician must explain any adjustment. NCI response and nutrition.
Results can take several weeks; the wait itself does not establish what the result will be. Ask when and how results will arrive and whom to contact if they do not. You can take a trusted person to the discussion. Further blood tests or scans may clarify the type and extent, but not everyone needs every test. Ask for an explanation and the next agreed step. NHS next steps.
ESGO’s optimal follow-up interval remains unsettled. Individual review checks symptoms, vulva and groins; tests depend on risks/findings. Skin conditions and late effects also need attention. Report changes between appointments. ESGO follow-up.
Laboratory evidence
Cell and animal findings can help investigate mechanisms; they do not establish a safe or effective human cancer regimen. No laboratory-derived supplement recommendation or personal dose is adopted here. Treatment choices require human evidence and clinical assessment.
The funding screen below distinguishes care guidance from independent efficacy. A guideline’s institutional production funding and author declarations do not resolve the financial chains of every referenced trial. Here, no comparative outcome estimate has passed that separate screen; this is a limitation of this review, not a claim that standard care lacks value.
Funding and source roles
Research funding at a glance
29 disclosure entries. The counts below summarize independence tiers explicitly assigned in this article. They count disclosures, not studies, funding amounts or evidence quality.
Consult this article’s source and funding notes for named funders, countries, relationships and exceptions where available. Institutional backing, researcher interests and trial sponsorship are separate questions. Public funding alone does not establish independence; commercial ties alone do not prove a claim false. This overview is not a new financial audit.
The source-specific map separates documented institutional funding from disease-page payments and trial sponsorship. Unknown allocations remain unknown. A public agency, charity or academic address does not by itself establish independent treatment efficacy.
| Source | Funding / backers | Country / jurisdiction | Independence | Credibility / incentives / gaps |
|---|---|---|---|---|
| NHS definition | DHSC; dated policy | UK | Tier 2 | B provisional; contributor/trial gaps. |
| NHS symptoms | DHSC; dated policy | UK | Tier 2 | B provisional; contributor/trial gaps. |
| NHS causes | DHSC; dated policy | UK | Tier 2 | B provisional; contributor/trial gaps. |
| NHS tests | DHSC; dated policy | UK | Tier 2 | B provisional; contributor/trial gaps. |
| NHS treatment | DHSC; dated policy | UK | Tier 2 | B provisional; contributor/trial gaps. |
| NHS support | DHSC; dated policy | UK | Tier 2 | B provisional; contributor/trial gaps. |
| NHS chemotherapy | DHSC; dated policy | UK | Tier 2 | B provisional; contributor/trial gaps. |
| NHS sepsis | DHSC; dated policy | UK | Tier 2 | B provisional; contributor/trial gaps. |
| NCI definition | Congress; institute finance | US | Tier 2 | B provisional; contributor/trial gaps. |
| NCI diagnosis | Congress; institute finance | US | Tier 2 | B provisional; contributor/trial gaps. |
| NCI stages | Congress; institute finance | US | Tier 2 | B provisional; contributor/trial gaps. |
| NCI treatment | Congress; institute finance | US | Tier 2 | B provisional; contributor/trial gaps. |
| NCI stage-based care | Congress; institute finance | US | Tier 2 | B provisional; contributor/trial gaps. |
| NCI chemotherapy | Congress; institute finance | US | Tier 2 | B provisional; contributor/trial gaps. |
| NCI professional PDQ | NCI; board payments; Stasenko disclosure; Filippova activity. | US; named leads New York | Tier 3 | C provisional; dated commercial interest, current contributor/trial money unclosed. |
| ESGO 2023 guideline | ESGO-funded; no external development funding. Author grants/advice/honoraria/travel include Medac, Roche, GSK, MSD; society route. | Lead Groningen, Netherlands | Tier 3 | C provisional; underlying study money unclosed. |
| NCCIH cancer safety | Appropriations; gifts. | US | Tier 2 | B provisional; dated review and named-contributor/trial gaps. |
| NHS website policy | Dated DHSC funding; no advertising/corporate sponsorship stated. Commissioned by NHS England; accounts. | UK | Tier 3 | B provisional; 2022 policy overdue. Page receipts and expert interests unknown. |
| NHS England accounts | Principal DHSC grant-in-aid; education/research/services/contracts, consolidated charges and charitable contributions. Parent/group differ. | UK; enquiry contact Leeds | Tier 3 | B provisional; statutory own 2025–26 accounts, exact website allocation unclosed. |
| NCI budget | Congressional appropriations; Gift Fund. | US | Tier 3 | B provisional; own FY2026 account, exact page/author allocation unclosed. |
| NCI gifts | Gift Fund separate from appropriations; project preferences allowed. Named page donors/receipts unknown. | Bethesda, Maryland, US contact | Tier 3 | B provisional; own receipt-route disclosure, not a full donor ledger. |
| PDQ board policy | Nongovernment meeting honoraria/travel; signed declarations and recusal; specific interests not publicly required. | US; international membership | Tier 3 | B provisional; own 2022 policy, individual receipts unclosed. |
| Stasenko 2025 disclosure | July 2024 GSK-sponsored advisory-board compensation; company. | NYU Langone, New York, US | Tier 3 | C provisional; full dated disclosure, fee/paying entity/PDQ allocation unknown. |
| Filippova 2023 activity | No relevant relationships declared for that activity; event supported by GSK, AstraZeneca, Seagen and Verastem. | US; Tampa event | Tier 3 | C provisional; historical scope, current interests and PDQ payments unknown. |
| GSK 2025 report | Medicine/vaccine sales; investors. | England/Wales incorporation; London, UK office | Tier 4 | D self-interest; own financial identity. Advisory payer/contract unclosed. |
| GSK investor information | Public shares/ADS; dated notified BlackRock and Dodge & Cox voting interests. | London, UK head/registered office | Tier 4 | D company disclosure; notifications not complete beneficial ownership or current all-holder audit. |
| ESGO sponsorship | Commercial partnerships fund education/training. Current full audited ledger and guideline allocation unclosed. | Current contact Brussels, Belgium | Tier 3 | C provisional; own mixed-income disclosure, no exact guideline grant inferred. |
| NCCIH appropriations | Congressional finance history through FY2024; Gift Fund. | Bethesda, Maryland, US contact | Tier 3 | B provisional; dated fiscal self-report, no current enacted amount/page allocation inferred. |
| NCCIH gifts | Conditional/unconditional donations/bequests; separate Gift Fund, appropriations cover operations. | Bethesda, Maryland, US gift office | Tier 3 | B provisional; own authority/receipt route, named donors/page payments unclosed. |
Frequently asked questions
Is vulvar cancer the same as vaginal cancer? No; the vulva is external. Exact site and histology matter. NHS definition.
Does an urgent referral mean I have cancer? No. Symptoms need examination, but other conditions can cause them. NHS symptoms.
Can VIN cream replace invasive treatment? No; precursor and invasive pathways differ. NCI options.
Can chemotherapy shivering wait? Contact the cancer team now; emergency signs require emergency services. NHS urgent advice; NHS emergency signs.
Sources and funding notes
Reviewed 5 October 2026. Adult invasive SCC; other pathways separate.
Professional PDQ names Filippova and Stasenko. Current complete personal interests and underlying study finance remain unclosed; no payment for this PDQ is inferred from other activities.
Ordinary NCI pages dated September 2024 lack named reviewers; the old patient-PDQ redirect does not establish current professional derivation.
NHS policy is a retained dated original; current accounts were read in selected scopes.
NCCIH safety is dated October 2021.
Countries describe sources, not treatment availability or manufacturing.
- NHS definition — Anatomy.
- NHS symptoms — Assessment and consent.
- NHS causes — Risk and prevention.
- NHS tests — Biopsy and results.
- NHS treatment — Treatment planning.
- NHS support — Support routes.
- NHS chemotherapy — Safety and coordination.
- NHS sepsis — Adult emergencies.
- NCI definition — Invasion boundary.
- NCI diagnosis — Tissue assessment.
- NCI stages — Extent and recurrence.
- NCI treatment — Treatment classes.
- NCI stage-based care — Selected options.
- NCI chemotherapy — Response and nutrition.
- NCI professional PDQ — Scope and reviewer context.
- ESGO 2023 guideline — Selected framework only.
- NCCIH cancer safety — Complementary safety.
- NHS website policy — Website finance only.
- NHS England accounts — Institutional finance only.
- NCI budget — Finance only.
- NCI gifts — Gift route only.
- PDQ board policy — Editorial process only.
- Stasenko 2025 disclosure — Financial-only named lead.
- Filippova 2023 activity — Dated declaration only.
- GSK 2025 report — Backer finance only.
- GSK investor information — Ownership/geography only.
- ESGO sponsorship — Society revenue/contact.
- NCCIH appropriations — Public funding route.
- NCCIH gifts — Gift authority/route.
Educational research reviewed 5 October 2026. Diagnosis and treatment require a qualified clinician; this article does not provide an individual prescription or replace urgent assessment.
Have a question — or want us to cover something?
Ask about anything on this page, or request the next deep dive: an ingredient, a supplement, or a health concern. We use published research, evidence syntheses, and regulatory guidance, with clear source links.
One daily research roundup
Get the topics, key findings and links from our new articles in one email. At most one digest a day, only when there is something new.